Clinical Trials
13 trialsNCT05294172 2026-05-08
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT03383094 2025-10-07
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Phase 2 Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT02624128 2023-11-13
V-CHANCE
National Cancer Institute, Naples
Phase 2 Unknown
NCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT04890522 2021-05-18
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT04361409 2020-04-28
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
China Medical University Hospital
Phase 1 Completed
NCT01309633 2019-07-22
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
National University Hospital, Singapore
Phase 2 Completed
NCT01360827 2014-06-17
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT01655628 2012-08-02
GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed